2.5. Inhibition Effect of Anti-IL-6R Antibody Treatment (Tocilizumab; ACTEMRA®) on Erk-1/-2 and STAT3 Signaling Transduction of Human CRC SW480 Xenografts Was Superior to the Treated Group of HT-29 Xenografts. This evidence concerns the gene IL6R and colorectal carcinoma.